Home › Funds › Lord Abbett › Lord Abbett Health Care Fund
Fund family: Lord Abbett · Filed by LORD ABBETT SECURITIES TRUST (CIK 898031) · SEC series S000064462
Share classes and tickers: LHCAX (C000208658), LHCCX (C000208659), LHCFX (C000208660), LHCIX (C000208662), LHCOX (C000208661), LHCQX (C000208664), LHCSX (C000208665), LHCTX (C000208667), LHCVX (C000208666)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 617 with, 10 against, 0 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 2 FOR, 10 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Lord Abbett’s manager page (20,995 ballot items across 30 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Lord Abbett | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.6% | 568 | 95.8% | 17,917 |
| Backed environmental and social shareholder proposals at US companies | n/a | 3 | 1.6% | 373 |
Each ballot item this fund voted is set against the votes of the other Lord Abbett funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Lord Abbett funds on all 288 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 71.3% of this fund’s 627 such votes could be given a sector; the other 180 (28.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 408 | 9 | 2.2% |
| Industrials | 18 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Technology | 4 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 331 | 0 |
| Compensation | 66 | 0 |
| Capital Structure | 62 | 0 |
| Audit-related | 59 | 0 |
| Say-on-Pay | 56 | 0 |
| Corporate Governance | 52 | 7 |
| Other Social Issues | 3 | 2 |
| Shareholder Rights and Defenses | 3 | 0 |
| Extraordinary Transactions | 2 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $1M | 10 | 2 |
| Gilead Sciences, Inc. | April 30, 2026 | $443,584 | 15 | 3 |
| Guardant Health, Inc. | June 17, 2026 | $354,170 | 5 | 0 |
| Natera, Inc. | June 11, 2026 | $332,040 | 8 | 0 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $296,078 | 13 | 0 |
| Tarsus Pharmaceuticals, Inc. | June 25, 2026 | $284,979 | 6 | 0 |
| Cencora, Inc. | March 5, 2026 | $243,171 | 13 | 0 |
| Johnson & Johnson | April 23, 2026 | $226,838 | 15 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 12, 2026 | IDEXX Laboratories, Inc. | Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposal | Against | For |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | Against | For |
635 ballot items at 61 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Lord Abbett Health Care Fund (LHCAX) voted at 61 shareholder meetings of 59 companies, on 635 ballot items in all. Where management made a recommendation, the fund followed it on 98.4% of the items and voted against it 10 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 12 shareholder proposals. It voted FOR the board's own proposals less often than Lord Abbett's funds as a whole (92.6% against 95.8%). It voted the same way as most Lord Abbett funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Lord Abbett’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.